Navigation Links
Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
Date:4/30/2013

GENEVA, April 30, 2013 /PRNewswire/ -- Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that it has closed an agreement with Ligand Pharmaceuticals Incorporated to sell potential milestone and royalty payments for more than 15 biologic development programs from Selexis.  

(Logo: http://photos.prnewswire.com/prnh/20120627/LA31604LOGO)

The acquired programs are in various preclinical and clinical stages. Funds from the Ligand deal will be used for R&D to further develop the next generation of SUREtechnology Platform™ products. Torreya Partners acted as financial advisor to Selexis. Selexis currently holds milestone and potential royalty interest payment rights to an additional 14 biologic development programs not included in the Ligand deal.

"With this truly innovative financing solution, Selexis was able to leverage a percentage of potential future revenues to fund, reinforce and expand our SUREtechnology Platform," said Dr. Igor Fisch , CEO, Selexis SA. "The non-diluting funds will support the growth of our products and technologies faster. The Company's SUREtechnology Platform is a powerful engine that continues to fuel royalty opportunities for Selexis." 

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin with
'/>"/>

SOURCE Selexis SA
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Selexis Announces Expansion of R&D License Agreement with Amgen
2. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
3. Microsofts Surface Pro Tablet Makes its Debut and Sells Out Fast; the Company was One of the Few to Defy the Dows Loss Yesterday
4. Cerecor Acquires Rights to NR2B Receptor Antagonist from Merck
5. Nephros Announces Rights Offering and Temporary Reduction in Exercise Price for March 2011 Warrants
6. Cerecor Acquires Rights to Merck COMT Inhibitors
7. Topokine Acquires Exclusive Rights to Revolutionary Technology for Manufacturing Topical Fat-Reducing Medications
8. Joe Gibbs Racing, BrightSky Launch Defy Diabetes Movement
9. Americans United for Life Celebrates Win for Illinois Conscience Rights in Case AUL Championed Since 2005
10. China Biologic Products, Inc. Adopts Stockholder Rights Plan
11. Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014 Though therapies are in their nascent ... show an annual increase of 16.2% over the 2010-2020 ... billion, according to Kalorama Information,s report, Stem Cell ... therapeutics that have gained or are expected to gain ... developers tackle ever more complicated conditions, stem cell therapies ...
(Date:10/30/2014)...   NxStage® Kidney Care, Inc ., a subsidiary of ... to host the grand opening ceremony of its ... th Street on November 20, 2014 from 3pm – ... staff who are committed to providing patients with enhanced access ... possible through more flexible dialysis treatment options.   ...
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
Breaking Medicine Technology:Report: Stem Cell Technologies Market Growing 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
... Minn., April 16, 2008 A new Mayo,Clinic ... protect against,mild cognitive impairment, a disorder of the ... This study will be presented at the,American Academy ... 16., Individuals with mild cognitive impairment can ...
... Support Moving Forward with a planned IND Filing for Novavax,s ... Seasonal Influenza Vaccine ... NVAX ) said today that it has received positive results ... influenza vaccine candidate. These findings will enable Novavax to,complete its ...
Cached Medicine Technology:Mayo Clinic Finds Exercise Can Reduce the Risk of Mild Cognitive Impairment 2Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate 2Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate 3
(Date:10/31/2014)... one out of four older Americans say that either ... unwanted medical treatment, according to the latest issue of ... Aging Report ( PP&AR ), which goes on ... when they fail to honor patients, end-of-life health care ... Illness Care: Issues and Options ," features 12 articles ...
(Date:10/31/2014)... Gold Medal Wine Club is making ... gifts for the wine novice and enthusiasts on their lists ... Special , which Early Bird shoppers receive discounts as high ... membership. , Gift Givers must place their orders before ... discounts, Gold Medal Wine Club adds more value to its ...
(Date:10/31/2014)... York (PRWEB) October 31, 2014 North ... Eye in Garden City, Long Island and the addition ... their medical staff, according to North Shore Eye Care ... the Emeritus Acting Chairman of the Department of Ophthalmology ... successful practice in Garden City for more than 30 ...
(Date:10/31/2014)... combination that can trigger the self-destruct process in lung ... according to research that will be presented at the ... next week*. , When healthy cells are no longer ... self destruction. But cancer cells swerve away from this ... grow out of control – causing tumours to form. ...
(Date:10/31/2014)... 31, 2014 FindSurrogateMother.com conveys ... gifts of life — building a family through surrogacy. ... mothers and donors with hopeful intended parents in turn ... , It’s a collective aptitude of surrogate mothers, intended ... and fertility clinics that help provide these connections — ...
Breaking Medicine News(10 mins):Health News:Advance directives can benefit patients, families, and health care system 2Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3
... Innovative Hospital Company Is Committed to Providing High ... Avanti Health System, LLC ("Avanti") is pleased ... LLC, including Memorial Hospital of Gardena ("MHG") and ... Corporation. MHG and ELADH have been providing quality ...
... 18 BeaconEquity.com announces the availability of Trade Alerts on ... daily trading notes for free by visiting: http://www.BeaconEquity.com/m ... JNJ ), Abbott Laboratories (NYSE: ABT ), Eli ... (NYSE: PFE ), Novartis AG (NYSE: ...
... Alive(TM) is the newest addition to the Company,s ... and BOULDER, Colo., Feb. 18 AdEx Media, ... online marketing, distribution, and consumer products company, today ... supplement, to its line of health and beauty ...
... ,Allscripts announced today that Edge Health Solutions, Inc. ... Allscripts Electronic,Health Record as "EdgeEHR(TM) Powered by Allscripts" ... management software on the Mac OS X(R),platform. , ... ) , Canada-based Edge ...
... new product packaging and ,e-commerce feature to company Web site - ... ... February 18, 2009 -- The Geritrex Corporation, a privately held pharmaceutical ... 30th year in business. Founded by CEO and registered pharmacist ...
... caution is warranted, experts say , , WEDNESDAY, Feb. 18 (HealthDay ... receiving human fetal stem cell therapy has been reported in ... contributed to the growths. , The tumors appeared ... years after he began receiving the neural fetal stem cell ...
Cached Medicine News:Health News:Avanti Health System Acquires Two Los Angeles Hospitals 2Health News:Avanti Health System Acquires Two Los Angeles Hospitals 3Health News:Avanti Health System Acquires Two Los Angeles Hospitals 4Health News:Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: JNJ, ABT, LLY, PFE, NVS, GSK 2Health News:AdEx Media Introduces Acai Alive(TM) 2Health News:AdEx Media Introduces Acai Alive(TM) 3Health News:Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform 2Health News:Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform 3Health News:Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform 4Health News:Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform 5Health News:A "Healthy" Company - Geritrex Celebrates Its 30 Year Anniversary with New Rebranding Effort and Expanding Distribution Channels 2
Codman periosteal elevators, sharp, length 8" (203 mm), blade width 3/16" (5 mm)....
Key periosteal elevators, blade width 1" (25 mm), total length 7 1/2" (191 mm)....
Cushing-Hopkins periosteal elevator, Gutsch handle, blade width 7/16" (11 mm), length 7 5/8" (194 mm)....
Cushing Little Joker periosteal elevators, solid handle, blade width 1/4" (6 mm), length 7 1/2" (191 mm)....
Medicine Products: